Incyte and Seagen face tricky launches
Black box warnings could limit the sales of their newly approved therapeutics.
Lilly’s lebrikizumab looks to outdo Dupixent
Lilly will soon discover whether its purchase of Dermira was wise.
Celldex looks beyond oncology for a resurgence
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Aclaris’s second crack at a topical Jak
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
Amgen follows Sanofi into a new dermatitis mechanism
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
